WeTrials
Completed

A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1)

What is this study?

This study is testing an investigational medication called retatrutide to see if it safely helps people with obesity or overweight lose weight. Researchers also want to see how the study drug affects related health conditions like knee joint pain and sleep breathing issues.

Who can participate?

You may be able to join if you do not have diabetes, have a higher body weight or body mass index, and meet certain health criteria like having high blood pressure or high cholesterol. People who have recently used weight loss medications, had weight loss surgery, or have a history of specific rare thyroid tumors cannot participate.

What will happen?

Participants will take either the study medication or a placebo, which looks like the medicine but has no active ingredients, once a week. The study lasts for about 89 weeks with up to 24 visits to monitor your health, weight, and overall well-being.

Where and when?

This study has locations in places like Arizona and Arkansas in the United States. The study status is currently completed.

Key Points
  • 1Testing a weekly investigational medication called retatrutide for weight management
  • 2Lasts about 89 weeks with up to 24 clinic visits
  • 3Open to adults with overweight or obesity who do not have diabetes

Related video

HCPLive: diabetes clinicians discuss the TRIUMPH-1 retatrutide results (May 2026)

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
ObesityOverweightOsteoarthritis, KneeObstructive Sleep Apnea

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.